araag2/HINT huggingface dataset:
Clinical trial NCT01359787 (phase 2, status: completed)
Conditions: atopic dermatitis, eczema
ICD codes: L20.89, L20.9, B00.0, L20.82, L20.84, L20.83, H01.131, H01.132, H01.133
Drugs: mapracorat, vehicle without active
SMILES: CC1=CC=C2C(NC[C@](O)(CC(C)(C)C3=CC(F)=CC4=C3OCC4)C(F)(F)F)=CC=CC2=N1, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Signed written informed consent

          -  Diagnosis of atopic dermatitis according to Hanifin and Rajka Criteria

          -  Willingness of subject to follow all study procedures

          -  Willingness to avoid excessive exposure of diseased areas to natural or artificial
             sunlight

        Exclusion Criteria:

          -  Pregnancy and breast-feeding

          -  Clinically relevant disease, which could interfere with the study conduct or the
             evaluation and interpretation of the study results

          -  Clinically manifested immunosuppressive disorder or known history of malignant disease

          -  History of relevant drug and/or food allergies
Clinical trial NCT00557700 (phase 2, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: administration of inhaled tiotropium bromide, administration of placebo
SMILES: [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Informed consent

          -  Male or female, at least 18 years old

          -  Documented medical history of asthma (diagnosis at least 6 months ago)

          -  Non-smoker or at least stopped for 1 year (in case smoked earlier: maximum of 10
             pack-years)

          -  Able to conduct a technically acceptable spirometry, methacholine and neurokinin-A
             provocation test.

          -  At visit 1: PC20 methacholine ≤ 8 mg/ml AND ≤ 3.3x10-7 mol/ml for the neurokinin-A
             provocation test.

          -  At visit 1: forced expiratory value in one second >= 80% of the predicted value.

          -  Female subjects may not get pregnant and should be using adequate contraception.

        Exclusion Criteria:

          -  Airway infection within 6 weeks prior to first study visit.

          -  Other respiratory diseases (eg COPD, lung cancer, etc.)

          -  Participating in another clinical trial.

          -  Clinically relevant systemic diseases, other than asthma.

          -  Clinically significant laboratory deviations.

          -  Alcohol or drug abuse.

          -  Female subjects who are lactating.
Clinical trial NCT00289627 (phase 2, status: completed)
Conditions: melanoma
ICD codes: C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4
Drugs: ipilimumab (mdx-010, bms-734016)
SMILES: COC1=CC=CC=C1OCC(O)CO
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with previously treated Stage III (unresectable)or Stage IV melanoma
Clinical trial NCT01367314 (phase 2, status: completed)
Conditions: impetigo
ICD codes: L01.00, L01.02, L01.03, L01.09, L01.01
Drugs: nvc-422
SMILES: CC(C)(CS(O)(=O)=O)N(Cl)Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects must be 2 - 12 years of age

          -  Parents or Legal Guardians must sign a written informed consent document

          -  Positive Gram stain of target lesion showing Gram-positive cocci;

          -  Clinical diagnosis of primary non-bullous impetigo as per the protocol

          -  Skin Infection Rating Scale total score of at least 4, with at least three of the five
             primary signs and symptoms present at baseline including a score of 1 or greater for
             exudate/pus;

          -  Screening within one day of enrollment into the study.

        Exclusion Criteria:

          -  Presence of other skin diseases at or near the investigational target area to be
             treated;

          -  Disease is so widespread or severe that, in the opinion of the investigator, oral
             antibiotic treatment is needed

          -  Active impetigo lesions greater than 5 cm2

          -  Signs and symptoms of a current infection requiring antibiotic treatment

          -  Use of systemic or topical antibiotics or steroids within 72 hours prior to study
             entry

          -  Females of childbearing potential
Clinical trial NCT00160069 (phase 2, status: completed)
Conditions: carcinoma, non small cell lung
ICD codes: D02.20, D02.21, D02.22
Drugs: sagopilone (bay86-5302, zk 219477), sagopilone (bay86-5302, zk 219477), sagopilone (bay86-5302, zk 219477)
SMILES: C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](CC=C)[C@H]1O)C1=CC=C2SC(C)=NC2=C1, C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](CC=C)[C@H]1O)C1=CC=C2SC(C)=NC2=C1, C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](CC=C)[C@H]1O)C1=CC=C2SC(C)=NC2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Non-small-cell lung cancer

          -  Only one previous chemotherapy with a platinum-containing drug

          -  Use of highly effective birth control methods in females of child-bearing potential

        Exclusion Criteria:

          -  No more than 1 previous chemotherapy for advanced disease

          -  Previous participation in another trial within the last 4 weeks

          -  Breast feeding

          -  Active infections
Clinical trial NCT01452347 (phase 2, status: terminated)
Conditions: heart valve diseases
ICD codes: I39
Drugs: warfarin 1mg, dabigatran etexilate intermediate dose, dabigatran etexilate low dose, warfarin 5mg, dabigatran etexilate high dose, warfarin 3mg
SMILES: CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2, CCCCCCOC(=O)\N=C(\N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C3=NC=CC=C3)N2C)C=C1, CCCCCCOC(=O)\N=C(\N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C3=NC=CC=C3)N2C)C=C1, CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2, CCCCCCOC(=O)\N=C(\N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C3=NC=CC=C3)N2C)C=C1, CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2
Eligibility criteria:

        Inclusion criteria:

          1. Patients aged 18-75

          2. Patients who have received a bileaflet mechanical heart valve

        Exclusion criteria:

          1. Prior valve surgery

          2. Uncontrolled hypertension

          3. severe renal impairment

          4. active liver disease

          5. increased risk of bleeding
Clinical trial NCT00471094 (phase 2, status: completed)
Conditions: esophagitis
ICD codes: B37.81, K20.0, K20.80, K20.81, K20.90, K20.91, K21.9
Drugs: ilaprazole, ilaprazole, ilaprazole, lansoprazole
SMILES: COC1=C(C)C(C[S+]([O-])C2=NC3=CC(=CC=C3N2)N2C=CC=C2)=NC=C1, COC1=C(C)C(C[S+]([O-])C2=NC3=CC(=CC=C3N2)N2C=CC=C2)=NC=C1, COC1=C(C)C(C[S+]([O-])C2=NC3=CC(=CC=C3N2)N2C=CC=C2)=NC=C1, CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1
Eligibility criteria:

        Inclusion Criteria:

          -  Subject must have endoscopically confirmed erosive esophagitis as defined by the Los
             Angeles (LA) Classification Grading System (A-D).

        Exclusion Criteria:

          -  Evidence of uncontrolled, clinically significant systemic disease; acquired
             immunodeficiency syndrome (AIDs); a condition likely to require surgery; cancer within
             5 years of screening; or abnormal laboratory values.

          -  Co-existing diseases affecting the esophagus; history of esophageal radiation therapy,
             cryotherapy, or physiochemical trauma.

          -  History of esophageal surgery or dilatation of an esophageal stricture other than
             Schatzki's ring; gastric or duodenal surgery except simple oversew of an ulcer.

          -  Active gastric or duodenal ulcers or acute upper gastrointestinal hemorrhage within 30
             days prior to screening.

          -  Current or history of Zollinger-Ellison syndrome or other hypersecretory conditions.

          -  Allergy to any proton pump inhibitor drug (omeprazole, lansoprazole, pantoprazole,
             rabeprazole, esomeprazole), any component of Ilaprazole, or antacid.

          -  Unable to tolerate lactose.

          -  Use of the following medications prior to randomization or anticipated use during the
             study: proton pump inhibitors, antacids, biphosphonates, histamine (H2) receptor
             antagonist (examples: Zantac, Tagamet), sucralfate, misoprostol, corticosteroids,
             prokinetics, Non-steroidal anti-inflammatory drugs (NSAIDs), strong anticholinergics,
             anticoagulant/anti-platelet aggregate therapy, anticoagulants, digoxin, theophylline,
             phenytoin.

          -  History of alcoholism or drug addiction.
Clinical trial NCT00361231 (phase 2, status: completed)
Conditions: biliary tract cancer, gallbladder adenocarcinoma
ICD codes: C24.9, C24.8, C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: bevacizumab, gemcitabine, oxaliplatin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed, locally unresectable or metastatic biliary tract or
             gallbladder adenocarcinoma. Patients must have at least one measurable lesion outside
             prior radiation field.

          -  Zero to one prior chemotherapy for biliary tract or gallbladder cancer

          -  Age > 18 years

          -  ECOG performance status 0-2

          -  Life expectancy > 12 weeks

          -  Adequate organ and bone marrow function

        Exclusion Criteria:

          -  Chemotherapy within past 3 weeks of initiation of therapy

          -  Pregnant or lactating women

          -  Clinically apparent central nervous system metastases or carcinomatous meningitis

          -  Biliary obstruction with inadequate drainage and total bilirubin > 2.5 mg/dL

          -  Concurrent malignancy of any site, except limited basal cell carcinoma or squamous
             cell carcinoma of the skin or carcinoma in situ of the cervix

          -  Uncontrolled serious medical or psychiatric illness

          -  Pre-existing peripheral neuropathy of grade 2 or greater severity according to the
             Common Terminology Criteria of the NCI (version 3.0)

          -  Current, recent (within 4 weeks of the first infusion of this study), or planned
             participation in an experimental drug study

          -  Blood pressure of > 150/100 mmHg

          -  Unstable angina

          -  NYHA Grade II or greater congestive heart failure

          -  History of myocardial infarction or stroke within 6 months

          -  Clinically significant peripheral vascular disease

          -  Evidence of bleeding diathesis or coagulopathy

          -  Major surgical procedure, open biopsy, or significant traumatic injury with 28 days
             prior to Day 1, anticipation of need for major surgical procedure during the course of
             the study

          -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess
             within 6 months prior to day 1

          -  Serious, non-healing wound, ulcer, or bone fracture
Clinical trial NCT00271271 (phase 2, status: completed)
Conditions: non small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: oxaliplatine / gemcitabine / vinorelbine
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Non-small cell bronchopulmonary cancer established by histological and/or cytological
             methods;

          -  Advanced or metastatic disease (stage IIIB or IV);

          -  At least one measurable lesion with one dimension (>= 20 mm by CT scan or >=10 mm by
             CT scan) outside of the irradiated area;

          -  No prior chemotherapy;

          -  Previous radiotherapy permitted as long as there has been a washout period of at least
             4 weeks;

          -  Age >= 18 years old;

          -  ECOG Performance Status (PS): 0-1;

          -  Life expectancy >3 months;

          -  Hepatic and renal functions and blood count satisfactory:

               -  Blood counts: white blood cells >= 3.0 x 10^9/l, neutrophils >= 1.5 x 10^9/l,
                  platelets >= 150 x 10^9/l, haemoglobin >= 9 g/dl,

               -  Hepatic function: bilirubin within the limit of the normal upper value, aspartate
                  transaminases (AST) or alanine transaminases (ALT) <= 2.5 times the normal upper
                  value

               -  Renal function: creatinine clearance (calculated according to Cockroft and Gault)
                  >= 40 ml/min;

          -  Patients of reproductive age must use an effective contraceptive method;

          -  Informed consent form signed before any procedure undertaken connected with the study

        Exclusion Criteria:

          -  Pregnant or breastfeeding patient;

          -  Past record of other cancers (excluding basocellular or epidermoid cutaneous carcinoma
             or cured carcinoma of the cervix);

          -  Symptomatic cerebral or leptomeningeal metastases;

          -  Symptomatic peripheral neuropathy > 1 (NCI-CTC grade);

          -  Presence of a serious disease or medical condition incompatible with the study (at the
             discretion of the investigator);

          -  Treatment with another test product or participation in another therapeutic trial in
             the 4 weeks preceding inclusion in the study;

          -  Concomitant treatment by any other anticancer therapy;

          -  Concomitant treatment with phenytoin.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Clinical trial NCT00413036 (phase 2, status: completed)
Conditions: lymphoma, non-hodgkin's
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: lenalidomide
SMILES: NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O
Eligibility criteria:

        Key Inclusion criteria

          -  Biopsy proven aggressive non-hodgkin's lymphoma

               -  Follicular center lymphoma Grade 3.

               -  Diffuse large B-cell lymphoma.

               -  Mantle cell lymphoma.

               -  Transformed lymphoma.

          -  Relapsed or refractory to previous therapy for lymphoma

          -  At least one prior combination chemotherapy regime

          -  Measurable disease on cross sectional imaging that is at least 2 cm in the longest
             diameter

          -  Eastern Cooperative Oncology Group (ECOG) performance score of 0, 1 or 2

          -  Willing to follow the pregnancy precautions

        Key Exclusion criteria

          -  Any of the following laboratory abnormalities.

               -  Absolute neutrophil count (ANC) < 1,500 cells/mm^3 (1.5*10^9/L).

               -  Platelet count < 60,000/mm^3 (60*10^9/L).

               -  Calculated creatinine clearance of <50mL/min

               -  Serum glutamic oxaloacetic transaminase/aspartate aminotransferase (SGOT/AST) or
                  Serum glutamic pyruvic transaminase/Alanine transaminase (SGPT/ALT) 5.0 times
                  upper limit of normal (ULN).

               -  Serum total bilirubin > 2.0 mg/dL (34 µmol/L)/conjugated bilirubin >0.8mg/dL.

          -  Subjects who are candidates for and willing to undergo an autologous stem cell
             transplant.

          -  History of active Central Nervous System (CNS) lymphoma within the previous 6 months

          -  History of other malignancies within the past year

          -  Positive Human immunodeficiency virus (HIV) or active Hepatitis B or C
Clinical trial NCT01159171 (phase 2, status: completed)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: bevacizumab [avastin], capecitabine [xeloda], oxaliplatin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Adult patients >=18 years of age

          -  Locally advanced or metastatic colorectal cancer

          -  No previous treatment with chemotherapy for metastatic disease

          -  Measurable and/or evaluable lesions

        Exclusion Criteria:

          -  Radiotherapy within 4 weeks before study

          -  Untreated brain metastases or primary brain tumors

          -  Chronic, daily treatment with high-dose aspirin (>325mg/day)

          -  Co-existing malignancies, or malignancies diagnosed within the last 5 years, with the
             exception of basal and squamous cell cancer, or cervical cancer in situ
Clinical trial NCT00665392 (phase 2, status: completed)
Conditions: head and neck cancer
ICD codes: C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, D36.11
Drugs: cisplatin, docetaxel, fluorouracil, cetuximab
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed squamous cell carcinoma of the oropharynx

               -  Stage III (T3 or T1-2, N1-2, M0) or nonmetastatic stage IV (T4 or T1-3, N3, M0)
                  disease

               -  Resectable disease

          -  Measurable or evaluable disease

          -  Tumor tissue available

        PATIENT CHARACTERISTICS:

        Inclusion criteria:

          -  WHO performance status 0-1

          -  ANC ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Hemoglobin ≥ 9 g/dL

          -  Creatinine < 1.5 times upper limit of normal (ULN)

          -  Creatinine clearance ≥ 60 mL/min

          -  AST and ALT < 5 times ULN

          -  Bilirubin < 1.5 times ULN

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  Affiliated with social security (including CMU)

        Exclusion criteria:

          -  Cardiovascular accident (myocardial infarction, cerebral vascular accident) within the
             past 6 months

          -  Serious and/or uncontrolled cardiac or respiratory disease (pulmonary fibrosis,
             interstitial pneumopathy)

          -  Other cancer within the past 5 years except for resected skin cancer, localized
             cutaneous or totally resected melanoma, or resected carcinoma in situ of the cervix

          -  Auditory condition precluding the use of cisplatin

          -  Contraindication due to psychological, social, or geographical reasons that may impede
             proper monitoring of treatment

          -  Persons under guardianship or trusteeship, or prisoners of law

        PRIOR CONCURRENT THERAPY:

          -  No prior treatment, including chemotherapy or radiotherapy

          -  No concurrent phenytoin, live attenuated vaccines, or parenteral aminoglycosides
Clinical trial NCT00305383 (phase 2, status: terminated)
Conditions: hepatitis c, chronic
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: viramidine, peginterferon alfa-2b
SMILES: NC(=N)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, N[C@@H](CCCNC(N)=N)C(O)=O
Reason stopped: 
    dose levels were determined to be subtherapeutic
  
Eligibility criteria:

        Inclusion Criteria:

          -  Treatment-naive, genotype 1 only, compensated, chronic hepatitis C infected Caucasian
             or African-American patients

          -  Body weight greater than 61 kg and not more than 87.3 kg

          -  HCV RNA greater than 2 million copies/mL

          -  Elevated measured or historical alanine aminotransferase

          -  Hemoglobin at least 12.0 g/dL for females and at least 13.0 g/dL for males

          -  Calculated creatinine clearance greater than 70 mL/min

        Exclusion Criteria:

          -  Cirrhosis of the liver

          -  Alanine aminotransferase greater than 3 times the upper limit of normal

          -  Severe neuropsychiatric disorders

          -  History or clinical manifestations of significant metabolic, hematological, pulmonary,
             ischemic, or unstable heart disease, gastrointestinal, neurological, renal,
             urological, endocrine, ophthalmologic disorders including severe retinopathy, or
             immune mediated disease

          -  Other co-morbid chronic viral infections including hepatitis B and the human
             immunodeficiency virus (HIV)
Clinical trial NCT00719810 (phase 2, status: completed)
Conditions: skin structure infections, bacterial skin diseases, staphylococcal skin infections
ICD codes: G00.3, M00.09, A05.0, M00.08, L00, M00.00, M00.011
Drugs: delafloxacin, delafloxacin, tigecycline
SMILES: NC1=NC(N2C=C(C(O)=O)C(=O)C3=CC(F)=C(N4CC(O)C4)C(Cl)=C23)=C(F)C=C1F, NC1=NC(N2C=C(C(O)=O)C(=O)C3=CC(F)=C(N4CC(O)C4)C(Cl)=C23)=C(F)C=C1F, [H][C@@]12CC3=C(C=C(NC(=O)CNC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2)N(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Adult (≥18 years of age) men or women with cSSSI

          -  Diagnosis of one of the following 3 types of cSSSI: wound infection that has developed
             within 30 days of surgery, trauma, or a bite injury; abscess that has developed in the
             7 days before enrollment; or cellulitis that has developed in the 7 days before
             enrollment

          -  Sexually active men and women of childbearing potential must agree to use an
             acceptable form of contraception, as determined by the investigator, during
             participation in the study and for 30 days after the final dose of study drug

          -  The patient must be willing to comply with protocol requirements

        Exclusion Criteria:

          -  Medical history of hypersensitivity or allergic reaction to quinolones, tetracycline
             or tetracycline derivatives

          -  Chronic or underlying skin condition at the site of infection

          -  Infection involving prosthetic materials or foreign bodies (unless prosthetic material
             will be removed within 24 hours), infection associated with a human bite,
             osteomyelitis, decubitus ulcer, diabetic foot ulcer, septic arthritis, mediastinitis,
             necrotizing fasciitis, myositis, tendinitis, endocarditis, toxic shock syndrome,
             gangrene or gas gangrene, burns covering ≥10% of body surface area, severely impaired
             arterial blood supply, current evidence of deep vein thrombosis or superficial
             thrombophlebitis

          -  An infection that would normally have a high cure rate after surgical incision alone

          -  Any infection expected to require other antimicrobial agents in addition to study drug

          -  Receipt of >24 hours of systemic antibiotic therapy in the 7 days before enrollment

          -  A severely compromised immune system

          -  History of Child-Pugh Class B or C liver disease or severe renal impairment
             (creatinine clearance of <30 mL/minute)

          -  Pregnancy or lactation